Abstract:Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity and uncontrolled drug release due to their lack of targeting. To improve the bioavailability of drugs and reduce side effects, we have developed a mixed micelle of nanomedicine composed of two prodrugs with surface modified monoclonal antibody for cancer therapy. In this system, Nimotuzumab was used as targeting ligands of the mixed micelles (named as DCMMs) that is composed of polymer-doxorubicin prodrug (abbreviated as PEG- b -P(GMA- ss -DOX)) and maleimide polyethylene glycol-chlorin e6 (abbreviated as Mal-PEG-Ce6). The mixed micelles modified with Nimotuzumab (named as NTZ-DCMMs) bind to overexpressed EGFR receptors on Hepatoma-22 (H22) cells. Disulfide bonds in PEG- b -P(GMA- ss -DOX) are disrupted in tumor microenvironment, inducing the reduction-responsive release of DOX and leading to tumor cell apoptosis. Simultaneously, Chlorin e6 (Ce6) produced plenty of singlet oxygen ( 1 O 2 ) under laser irradiation to kill tumor cells. In vivo biological distribution and antineoplastic effect experiments demonstrate that NTZ-DCMMs enhanced drug enrichment at tumor sites through targeting function of antibody, dramatically suppressing tumor growth and mitigating cardiotoxicity of drugs. All results prove that NTZ-DCMMs have the ability to actively target H22 cells and quickly respond to tumor microenvironment, which is expected to become an intelligent and multifunctional drug delivery carrier for efficient chemotherapy and photodynamic therapy of hepatoma. Statement of significance Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity due to their lack of targeting. Therefore, it's necessary to develop effective, targeted, and collaborative treatment strategies. We construct a mixed micelle of nanomedicine based on two polymer prodrugs and modified with monoclonal antibody on surface for cancer therapy. Under the tumor cell microenvironment, the disulfide bonds of polymer- ss -DOX were broken, effectively triggering DOX release. The photosensitizer Ce6 could generate a large amount of ROS under light, which synergistically promotes tumor cell apoptosis. By coupling antibodies to the hydrophilic segments of polymer micelles, drugs can be specifically delivered. Compared with monotherapy, the combination of chemotherapy and photodynamic therapy can significantly enhance the therapeutic effect of liver cancer.

pH-responsive dual-drug nanomicelles for co-delivery of DOX and Ce6 for combination therapy of tumors

A co-delivery system based on chlorin e6-loaded ROS-sensitive polymeric prodrug with self-amplified drug release to enhance the efficacy of combination therapy for breast tumor cells

A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy

“Against the tide, nothing to hide”- the saga of a community neurosurgeon

Dual-responsive Doxorubicin-Loaded Nanomicelles for Enhanced Cancer Therapy.

Study on the application of hollow mesoporous polydopamine as nanoparticle drug carrier in tumor combination therapy

pH/near-infrared light dual activated Ce6-doped silicon nanoparticles with tumor chemo-photodynamic synergistic therapy for improving efficiency of monotherapy

Immunotherapy with ligands of natural killer T cells.

Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy

NIR-/pH-Responsive Nanocarriers Based on Mesoporous Hollow Polydopamine for Codelivery of Hydrophilic/Hydrophobic Drugs and Photothermal Synergetic Therapy.

ROS-Responsive Polymeric Nanocarriers with Photoinduced Exposure of Cell-Penetrating Moieties for Specific Intracellular Drug Delivery

The atypical becomes typical: the work of oncology nurses.

A Nanomedicine Composed of Polymer- ss -DOX and Polymer-Ce6 Prodrugs with Monoclonal Antibody Targeting Effect for Anti-tumor Chemo-Photodynamic Synergetic Therapy

C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types.

Ph-Responsive Polymeric Micelles Based on Poly(2-Ethyl-2-oxazoline)-poly(d,l-lactide) for Tumor-Targeting and Controlled Delivery of Doxorubicin and P-glycoprotein Inhibitor

ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer

Acid-sensitive polymeric prodrug micelles for achieving enhanced chemo-photodynamic therapy

Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy

Stimuli-Sensitive Linear-Dendritic Block Copolymer-Drug Prodrug as a Nanoplatform for Tumor Combination Therapy

Dual‐Targeting Photosensitizer‐Peptide Amphiphile Conjugate for Enzyme‐Triggered Drug Delivery and Synergistic Chemo‐Photodynamic Tumor Therapy

"Transforming enemy into friend" strategy-based stimuli responsive dual-drug liposomes for synergistic chemo-photodynamic therapy